New psoriasis drug shows promise in early trial

NCT ID NCT01585233

Completed Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a study tested an experimental drug called ASKP1240 in 60 adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo intravenously. The main goals were to check safety, how the drug moves through the body, and early signs of effectiveness, such as changes in psoriasis severity scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASKP1240 (an experimental drug given intravenously)
What this could lead to: If successful, this could point toward a new treatment option for moderate to severe plaque psoriasis.
What could go wrong: This is an early phase 2a trial with only 60 participants, so results may not apply to everyone. The drug is still experimental and may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Locations

Auckland Clinical Studies

Auckland, 1010, New Zealand
CMAX

Adelaide, Victoria, 5000, Australia
Christchurch Clincial Studies Trust, Ltd.

Christchurch, 8011, New Zealand
Durondel C.P. Inc, The Dermatology Clinic

Moncton, New Brunswick, E1C 8X3, Canada
Epworth Hospital

Richmond, Victoria, 3121, Australia
Innovaderm Research, Inc.

Montreal, Quebec, H2K 4L5, Canada
K. Papp Clinical Research

Waterloo, Ontario, N2J 1C4, Canada
Linear Research

Nedlands, Western Australia, 6009, Australia
New Lab Clinical Research

St. John's, Newfoundland and Labrador, A1C 2H5, Canada
P3 Research, Tauranga

Tauranga, 3110, New Zealand
P3 Research, Wellington

Wellington, 6021, New Zealand
Specialist Connect

Brisbane, Queensland, 4102, Australia
Ultranova Skincare

Barrie, Ontario, L4M 6L2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.